NASDAQ:SPPI

Spectrum Pharmaceuticals Stock Forecast, Price & News

$3.59

-0.20 (-5.28 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.59

Now: $3.59▼

$3.83

50-Day Range

$3.38

MA: $4.17▼

$5.14

52-Week Range

$1.74

Now: $3.59▼

$5.24

Volume1.34 million shs

Average Volume1.67 million shs

Market Capitalization$523.86 million

P/E RatioN/A

Dividend YieldN/A

Beta2.22

Spectrum Pharmaceuticals, Inc., a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNÃ¡, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. for interferon therapeutics drug delivery platform. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

MarketRank^™

Overall MarketRank^™

1.53 out of 5 stars

Medical Sector

329th out of 1,558 stocks

Pharmaceutical Preparations Industry

175th out of 638 stocks

3.4 Analyst's Opinion

Consensus Rating
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.75, Spectrum Pharmaceuticals has a forecasted upside of 171.6% from its current price of $3.59.
Amount of Analyst Coverage
Spectrum Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Spectrum Pharmaceuticals has received 469 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Spectrum Pharmaceuticals has received 364 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Spectrum Pharmaceuticals has received 56.30% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote “Outperform” if you believe SPPI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Spectrum Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Spectrum Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Spectrum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,551,106.00 in company stock.
Percentage Held by Insiders
Only 5.04% of the stock of Spectrum Pharmaceuticals is held by insiders.
Percentage Held by Institutions
49.73% of the stock of Spectrum Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($1.39) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Spectrum Pharmaceuticals is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Spectrum Pharmaceuticals is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Spectrum Pharmaceuticals has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:SPPI

Previous Symbol

CUSIP84763A10

CIK831547

Webwww.sppirx.com

Phone702-835-6300

Employees146

Debt

Debt-to-Equity RatioN/A

Current Ratio3.15

Quick Ratio3.15

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$109.33 million

Price / Sales4.79

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.69 per share

Price / Book2.12

Profitability

EPS (Most Recent Fiscal Year)($1.14)

Net Income$-112,690,000.00

Net MarginsN/A

Return on Equity-76.09%

Return on Assets-55.80%

Miscellaneous

Outstanding Shares145,922,000

Market Cap$523.86 million

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$3.59

-0.20 (-5.28 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

How has Spectrum Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Spectrum Pharmaceuticals' stock was trading at $2.39 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPPI stock has increased by 50.2% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19.

Is Spectrum Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Spectrum Pharmaceuticals stock.
View analyst ratings for Spectrum Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Spectrum Pharmaceuticals?

Wall Street analysts have given Spectrum Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Spectrum Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Spectrum Pharmaceuticals' next earnings date?

Spectrum Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Spectrum Pharmaceuticals.

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Wednesday, November, 4th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.02.
View Spectrum Pharmaceuticals' earnings history.

What price target have analysts set for SPPI?

4 brokerages have issued 1-year target prices for Spectrum Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $9.75 in the next twelve months. This suggests a possible upside of 171.6% from the stock's current price.
View analysts' price targets for Spectrum Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Spectrum Pharmaceuticals' key competitors?

Some companies that are related to Spectrum Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Novavax (NVAX).
View all of SPPI's competitors.

What other stocks do shareholders of Spectrum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the following people:

Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 63, Pay $1.4M)
Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 53, Pay $937.46k)
Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 45, Pay $1.01M)
Mr. Keith M. McGahan J.D., L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 45, Pay $823.28k)
Dr. Francois Lebel FRCPC, M.D., Exec. VP & Chief Medical Officer (Age 69, Pay $854.04k)
Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
Mr. Bimal R. Shah, VP of Corp. & Bus. Devel.
Mr. Alberto Dejesus, VP of Marketing
Ms. Lisa A. Croissant, VP of Sales
Dr. Zane Yang M.D., Sr. VP of Clinical Devel.

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Who are Spectrum Pharmaceuticals' major shareholders?

Spectrum Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%). Company insiders that own Spectrum Pharmaceuticals stock include Anthony E Maida III, Dolatrai Vyas, Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Stuart Mitchell Krassner, Thomas J Riga and William Ashton.
View institutional ownership trends for Spectrum Pharmaceuticals.

Which institutional investors are selling Spectrum Pharmaceuticals stock?

SPPI stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Francois Lebel, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Thomas J Riga, and William Ashton.
View insider buying and selling activity for Spectrum Pharmaceuticals or view top insider-selling stocks.

How do I buy shares of Spectrum Pharmaceuticals?

Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of SPPI stock can currently be purchased for approximately $3.59.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $523.86 million and generates $109.33 million in revenue each year. The biotechnology company earns $-112,690,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Spectrum Pharmaceuticals employs 146 workers across the globe.

What is Spectrum Pharmaceuticals' official website?

The official website for Spectrum Pharmaceuticals is www.sppirx.com.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here